IN THE CLAIMS (37 CFR 1.121 Revised)

Cancel claims 7-9.

1. (currently amended) A compound of the Formula I



I

or the pharmaceutically acceptable salts thereof,
wherein: X is



each n is independently 1 to 3 inclusive;

X^1 and X^2 are independently hydrogen or C_1-C_8 alkyl, or -$(CH_2)_y$-Z;

y is 0 to 4 inclusive;

Z is hydrogen, C_1-C_8 alkyl, C_3-C_8 cycloalkyl, C_1-C_8 perfluoroalkyl, C_2-C_8 alkenyl, ~~phenyl, substituted phenyl, naphthyl, substituted naphthyl~~,-OH, -OC_1-C_8 alkyl, -SC_1-C_8 alkyl,-SO_3H, -CO_2H,

-CO_2C_1-C_8 alkyl,

-$CN(C_1$-C_8alkyl$)_2$, -NH_2, -$NH(C_1$-C_8alkyl),

-$N(C_1$-C_8alkyl$)_2$, -NCC_1-C_8 alkyl, guanidinyl, thienyl, imidazolyl, thiazolyl, or indolyl, phenyl, substituted phenyl wherein 1-4 substituents are present each independently selected from a group consisting of halogen, -OH, -CF3, -NO2, -NH2, -NH(C1-C6alkyl), N(C1-C6alkyl)2, C1-C6 alkyl, -OC1-C6 alkyl, -CN, -CF3, -CO2H, and CO2C1-C6 alkyl, naphthyl, substituted naphthyl wherein a substituent is selected from a group consisting of halogen, -OH, -CF3, -NO2, -NH2, -NH(C1-C6alkyl), N(C1-C6alkyl)2, C1-C6 alkyl, -OC1-C6 alkyl, -CN, -CF3, -CO2H, and CO2C1-C6 alkyl;

R^1 [and R^2 are independently] is C_1 -C_8alkyl or -$(CH_2)_n$-C_3-C_6cycloalkyl, -$(CH_2)_n$-phenyl, and R^2 is C_4 -C_8alkyl or -$(CH_2)_n$-C_3-C_6cycloalkyl, -$(CH_2)_n$-phenyl, or R^1 and R^2 taken together with the nitrogen atom to which they are attached to form a cyclic structure selected from


,

,

, or

;

where R^3 and R^4 independently are hydrogen, C_1-C_8 alkyl, $(CH_2)_n$-phenyl, or $(CH_2)_n$-cycloalkyl; R^5 is hydrogen, C_1-C_8 alkyl, halogen or $-CF_3$;
and each m is 2 to 8 inclusive.

2. (currently amended) The compounds:

~~(Z) [5-(4-Diethylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid~~;
(Z) [5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
~~(Z) [5-(4-Dipropylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid~~;
(Z) [5-(4-Diisobutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) [5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) (5-{4-[Bis-(3-methyl-butyl)-amino]-benzylidene}-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid;
(Z) [5-(4-Azepan-1-yl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) [5-(4-Dihexylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) {5-[4-(Methyl-octyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; or
(Z) {5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid.

3. (currently amended) The compounds:

(Z) {5-[4-(Cyclopropylmethyl-propyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) {5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) {5-[4-(Methyl-phenethyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) {5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid;
(Z) {5-[4-(Butyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) {5-[4-(Butyl-ethyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

(Z) {5-[4-(Benzyl-butyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) [5-(4-Dioctylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) 4-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;

(Z) 3-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 3-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid;
(Z) 4-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acid;
(Z) 4-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acid;
(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid;
(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-phenyl-propionic acid;
(Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-(3H-imidazol-4-yl)-propionic acid;
(Z) {5-[4-(Hexyl-methyl-amino)-naphthalen-1-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

(Z) [4-Oxo-5-(4-pyrrolidin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) {5-[4-(4-Butyl-piperazin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) (4-Oxo-5-{4-[4-(3-phenylpropyl)piperidine-1-yl]-benzylidene}-2-thioxo-thiazolidin-3-yl)-acetic acid;
(Z) {5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 3-[4-Oxo-5-(4-perhydro-azepin-1-yl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid;
(Z) 4-{5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) {4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}-butyric acid;
~~(Z) [5-(1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid~~;
(Z) 3-{5-[(4aS,8aR)-4-(octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-{5-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) [4-Oxo-5-(4-piperidin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl}acetic acid;
(Z) 3-{5-[(4aS,8aS)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-[4-Oxo-5-(4-perhydro-azepin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]-butyric acid;
(Z) 4-{5-[(4aS,8aS)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;

(Z) 3-[4-Oxo-5-(4-piperidine-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]propionic acid;
(Z) 4-[4-Oxo-5-(4-piperidine-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl}butyric acid;
(Z) {5-[(4-azocan-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) {5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) {5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) [5-(1-Butyl-2,3-dihydro-1H-indol-5-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
(Z) 4-{5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) 3-{5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 3-{5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) {5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 4-[4-Oxo-5-(4-azocan-1-yl-benzylidene)-2-thioxo-thiozolidine-3-yl]butyric acid;
(Z) 4-{5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) 4-{5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) 3-[4-Oxo-5-(4-perhydro-azacin-1-yl-benzylidene)-2-thioxo-thiazolidine-3-yl]propionic acid;
~~(Z) 3-[5-(1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid~~;
~~(Z) 4-[5-(1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acid~~;
(Z) {5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-{5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) {5-[4-(4-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{5-[4-(4-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-{5-[4-(3-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
(Z) {5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
(Z) 3-{5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
(Z) 4-{5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid.

4. (original) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.

5. (original) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 3.

6. (currently amended) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 4 2.

7-9 (CANCELED)

10. (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
    a. introducing into a patient a detectable quantity of a labeled compound of Claim 1;
    b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
    c. detecting the labeled compound associated with the amyloid deposits.

11. (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
    a. introducing into a patient a detectable quantity of a labeled compound of Claim 3;
    b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
    c. detecting the labeled compound associated with the amyloid deposits.

12. (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
    a. introducing into a patient a detectable quantity of a labeled compound of Claim 4;
    b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
    c. detecting the labeled compound associated with the amyloid deposits.

13. (withdrawn) The method of Claim 11 wherein the patient has or is suspected to have Alzheimer's disease.

14. (withdrawn) The method of Claim 12 wherein the patient has or is suspected to have Alzheimer's disease.

15. (withdrawn) The method of Claim 13 wherein the patient has or is suspected to have Alzheimer's disease.

16. (withdrawn) The method of Claim 11 wherein the labeled compound is a radiolabeled compound.

17. (withdrawn) The method of Claim 12 wherein the labeled compound is a radiolabeled compound.

18. (withdrawn) The method of Claim 13 wherein the labeled compound is a radiolabeled compound.

19. (withdrawn) The method of Claim 11 wherein the labeled compound is detected using MRI.

20. (withdrawn) The method of Claim 12 wherein the labeled compound is detected using MRI.

21. (withdrawn) The method of Claim 13 wherein the labeled compound is detected using MRI.

22. (original) A pharmaceutical composition comprising a compound of Claim 1 together with an excipient, diluent, or carrier therefor.

23. (original) A pharmaceutical composition comprising a compound of Claim 3 together with an excipient, diluent, or carrier therefor.

24. (currently amended) A pharmaceutical composition comprising a compound of Claim [4]2 together with an excipient, diluent, or carrier therefor.
sulfone; and